Effective relief from chronic hypersensitive pain states remains an unmet need. Here we report the discovery that the TRPM8 ion channel, co-operating with the 5-HT 1B receptor (5-HT 1B R) in a subset of sensory afferents, exerts an influence at the spinal cord level to suppress central hypersensitivity in pain processing throughout the central nervous system. Using cell line models, ex vivo rat neural tissue and in vivo pain models, we assessed functional Ca 2+ fluorometric responses, protein:protein interactions, immuno-localisation and reflex pain behaviours, with pharmacological and molecular interventions. We report 5-HT 1B R expression in many TRPM8-containing afferents and direct interaction of these proteins in a novel multi-protein signalling complex, which includes phospholipase D1 (PLD1). We provide evidence that the 5-HT 1B R activates PLD1 to subsequently activate PIP 5-kinase and generate PIP 2 , an allosteric enhancer of TRPM8, achieving a severalfold increase in potency of TRPM8 activation. The enhanced activation responses of synaptoneurosomes prepared from spinal cord and cortical regions of animals with a chronic inflammatory pain state are inhibited by TRPM8 activators that were applied in vivo topically to the skin, an effect potentiated by co-administered 5-HT 1B R agonists and attenuated by 5-HT 1B R antagonists, while 5-HT 1B R agents alone had no detectable effect.
Introduction
When chronic pain becomes established, its treatment is problematic because of the lasting molecular and functional changes that occur within the nervous system. One promising new target for chronic pain relief is the TRPM8 cation-permeable ion channel, which is expressed in a subset of primary afferent sensory neurons.
TRPM8 is activated by cooling below 23 o C (McKemy et al., 2002; Peier et al., 2002) and there is strong evidence for its physiological role as a cool sensor (Bautista et al., 2007; Colburn et al., 2007; Dhaka et al., 2007; Knowlton et al., 2013) . Matching an empirical understanding held since classical Greek times, activation of TRPM8 by mild cooling or the selective chemical activators icilin and menthol produces robust analgesia in chronic hypersensitive pain models (Dhaka et al., 2007; Knowlton et al., 2013; Liu et al., 2013; Proudfoot et al., 2006; Su et al., 2011) and may even attenuate some basal responses to noxious stimuli (Harrington et al., 2011; Klein et al., 2010) . Correspondingly, TRPM8 activation can provide analgesia in a clinical setting (Colvin et al., 2008; Storey et al., 2010) . Topical application of low concentrations of TRPM8-activating agents is an effective route for producing analgesia in both laboratory and clinical settings (Colvin et al., 2008; Proudfoot et al., 2006; Storey et al., 2010) , consistent with evidence for a concentration of TRPM8-expressing nerve terminals in epidermis and around the epidermal/dermal border (Dhaka et al., 2008; Takashima et al., 2007 ). It appears that TRPM8-expressing afferents act centrally in the spinal cord to suppress inputs from the much larger population of nociceptive afferents (Proudfoot et al., 2006; Su et al., 2011; Zheng et al., 2010) . The mechanism of interaction may involve inhibitory metabotropic glutamate receptors and GABAergic inhibitory interneurons in superficial dorsal horn (Proudfoot et al., 2006; Zheng et al., 2010) , although an unidentified peripheral component may also contribute (Harrington et al., 2011) . TRPM8 could play a part in the cool allodynia associated with chronic sensitised pain states (Su et al., 2011; Xing et al., 2007) , which might be anticipated from its role as the primary sensor of cool temperatures, rather than implying any direct role in processes of hypersensitivity. Knockout or ablation of TRPM8 however, only partially abrogates cool allodynia (Knowlton et al., 2013) . It has also been suggested that TRPM8 can contribute to noxious cold responses and peripheral administration of TRPM8 activators at high concentrations can induce hyperalgesia (Dhaka et al., 2007; Gentry et al., 2010; Klein et al., 2010; Knowlton et al., 2010; Proudfoot et al., 2006; Wasner et al., 2004) .
In trigeminal and dorsal root ganglia TRPM8 is selectively expressed in a small discrete subpopulation of Cand Aδ-afferents, which express the Nerve Growth Factor receptor TrkA but are generally distinct from the much larger populations expressing the nociceptor markers TRPV1, TRPA1, CGRP or lectin IB4-binding sites (Dhaka et al., 2008; Kobayashi et al., 2005; McKemy et al., 2002; Peier et al., 2002; Pogorzala et al., 2013; Proudfoot et al., 2006; Takashima et al., 2007) . Only a minority of somatosensory TRPM8 afferents co-express TRPV1 and these may correspond to cells with low TRPM8:Kv1 channel ratios and tetrodotoxin-resistant Na + channels that respond only to more severely cold (noxious) temperatures (Madrid et al., 2009; Sarria et al., 2012) . Elements of any noxious effects observed with high concentrations of TRPM8 activators may involve such high-threshold afferents or off-target effects on other channels. In some visceral afferents, TRPM8/TRPV1 co-existence may be more common, where TRPM8 has been suggested to act peripherally to modify nociceptive responses through an unknown mechanism (Harrington et al., 2011; Hayashi et al., 2009 ).
As TRPM8 activator-induced analgesia becomes more apparent in hypersensitive pain states (Proudfoot et al., 2006) , we hypothesised that the TRPM8 channel may be potentiated by an endogenous factor released in chronic pain conditions. Such mediators include 5-HT, which as well as being released peripherally at sites of injury can be released from bulbospinal pathways into the spinal dorsal horn where it could potentially influence the central terminals of afferents (el-Yassir and Fleetwood-Walker, 1990; Khalil and Helme, 1990; Shu and Mendell, 1999) . A variety of 5-HT receptor subtypes is expressed in dorsal root ganglia (DRG) (Chen et al., 1998; Nicholson et al., 2003; Pierce et al., 1997) . One candidate with potentially appropriate characteristics is the 5-HT 1B receptor (5-HT 1B R), which is reported to exert an antinociceptive influence (Alhaider and Wilcox, 1993; el-Yassir et al., 1988; Granados-Soto et al., 2010; Kayser et al., 2007) .
Furthermore, the 5-HT 1B R is associated with TrkA-positive Aδ-afferents in trigeminal ganglia (Wotherspoon and Priestley, 2000) , (which could in part correspond to TRPM8-containing afferents) and is more widely expressed in DRG (Classey et al., 2010) , where TRPM8 expression is increased in both Aδ and C-type afferents by neuropathic pain (Proudfoot et al., 2006) . We therefore looked here for any functional or molecular evidence in support of a facilitatory interaction between the 5-HT 1B R and TRPM8.
Materials and methods

In vivo studies -pain models and drug administration
All experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and associated guidelines and had received approval from the University of Edinburgh ethical committee. Male
Wistar rats (Harlan, UK), weight between 180-250 g, were used in all experiments and were given access to food and water ad libitum and housed in accordance with Home Office guidelines. Intraplantar injection of Complete Freund's Adjuvant (CFA) was used to model chronic inflammatory pain (Taurog et al., 1988) .
Following brief anaesthesia with a 4% isoflurane/oxygen mixture, the plantar surface of the right hindpaw was sterilised with 0.05% Hibitane (Zeneca, UK), before 150 µl of 50% CFA (Sigma; 1 mg Mycobacterium tuberculosis suspension in 0.85 ml mineral oil and 0.15 ml mannide mono-oleate) in 0.9% saline was injected between the toes and towards the middle of the paw, avoiding the ankle. Ipsilateral thermal reflex hypersensitivity developed within 24 h and remained substantial for up to 2 weeks. The sciatic nerve chronic constriction injury (CCI) preparation was used as a model of chronic neuropathic pain (Bennett and Xie, 1988) .
Animals were anaesthetised with a 4% isoflurane/oxygen mixture (Zeneca, Cheshire, UK) before exposure of the sciatic nerve, proximal to the trifurcation at mid-thigh level. Four loose ligatures of chromic catgut (SMI AG, Hunningen, Belgium) were tied around the nerve, separated by 1 mm. CCI rats consistently developed ipsilateral thermal reflex hypersensitivity, which peaked between days 9 and 16 post-surgery, when drug testing was carried out. For quantitative sensory testing, animals were initially habituated to the tests on a minimum of 3 occasions in order to establish consistent reponses. Sensitivity to a noxious thermal stimulus was assessed by measuring paw withdrawal latency (in s) elicited by an infrared beam (55°C, Hargreaves' thermal stimulator, Linton Instrumentation, Diss, UK) directed to the mid-plantar glabrous skin of the hind paw. Withdrawal responses were only noted when they indicated clear nocifensive flicking behaviour and their latencies were recorded to the nearest 0.1 s. A maximum cut-off latency of 20 s and a minimum of 5 min recovery time between tests were established in order to prevent tissue damage. Prior to drug application, at least 3 pre-drug tests were performed to produce a mean baseline value. Testing commenced 10-15 min after drug administration under anaesthesia in order to allow full functional recovery and tests were then repeated every 10 min for up to 60 min. For intrathecal application, drugs were injected in a volume of 50 µl by percutaneous puncture into the L5/6 intervertebral space of rats anaesthetised with 3% isoflurane/oxygen (Proudfoot et al., 2006) . The vehicle for drug injections was saline with up to 0.5% dimethylformamide and had no effect alone on behavioural reflex responses. For topical administration, drugs were dissolved in either 1% aqueous dimethylformamide or propan 1,2-diol (Thermo-Fisher) containing 1.5% caprolactam (Brilliance Biochemical Co Ltd, Beijing, China), a vehicle that facilitates skin penetration of hydrophilic compounds (Williams, 2003) , and applied topically to cover both hindpaws for 15 min prior to tissue removal, in rats anaesthetised with 3% isoflurane/O 2 . The vehicles had no discernible effect alone. The following drugs were applied in appropriate combinations: the selective TRPM8 agonists, icilin, 3,4-dihydro-3-(2-hydroxyphenyl)-6-(3-nitrophenyl)- concentrations of topically applied drugs that are reached adjacent to the TRPM8-containing nerve terminals in the epidermis or around the dermal/epidermal boundary are not known but are likely to be greatly reduced compared to those delivered to the skin surface.
In vivo studies -acute behavioural effects of TRPM8 activators
To evaluate whether alternative acute responses to administration of TRPM8 activators were modulated by 5-HT 1B R agents, we first quantified "wet dog shakes" induced by intraperitoneal injection of icilin (Wei, 1981; Werkheiser et al., 2009) . Rats were briefly anaesthetised with 3% isoflurane/oxygen and injected at 1 ml/kg with icilin (0.5 mg/kg; 1.6 mM solution), icilin (0.5 mg/kg) plus sumatriptan (0.3 mg/kg; 1.0 mM solution), icilin (0.5 mg/kg) plus SB 224289 (3 mg/kg; 5.4 mM solution) or vehicle (1% Tween-80 with 8% dimethylformamide in de-ionised water). Doses were chosen on the basis of literature studies demonstrating efficacy (Stean et al., 2005; Vera-Portocarrero et al., 2008; Werkheiser et al., 2009 ). After 5 min recovery, shaking events were recorded by two independent observers over the following 20 min. In addition we investigated the nocifensive (flinching and paw lifting) behaviour elicited by direct intraplantar injection of icilin at high concentrations (Knowlton et al., 2010) . Rats were briefly anaesthetised with 3% isoflurane/oxygen and received a subcutaneous intraplantar injection of 80 µg icilin in 75 µl of 1% Tween-80 with 16% dimethylformamide in de-ionised water (3.2 mM solution), either alone or additionally containing 45 µg CP 94253 (2 mM solution). Doses were chosen wherever possible on the basis of literature studies demonstrating efficacy (Gentry et al., 2010; Godinez-Chaparro et al., 2013; Knowlton et al., 2010) . After 5 min recovery, flinching and paw lifting events were recorded by two independent observers over the following 20 min.
Dual label immunofluorescence histochemistry
DRGs from spinal segments L4-6 were dissected, rapidly embedded in OCT cryo-sectioning medium (CellPath) and frozen on dry ice. 16 µm sections were cut by cryostat and mounted onto poly-L-lysine coated slides (VWR International). Sections were washed in PBS and then incubated for 1 h at room temperature in blocking buffer (10% normal donkey serum, 4% fish skin gelatin, 0.2% Triton X-100 in PBS) prior to overnight incubation at 4°C with a combination of primary antibodies in buffer (4% normal donkey serum, 4% fish skin gelatin, 0.2% Triton X-100 in PBS). Primary antibodies were used as follows: rabbit polyclonal anti-TRPM8 (Alomone) 1:300 and goat polyclonal anti-5-HT 1B R (Santa Cruz Biotechnology) 1:150. Sections were washed in PBS and incubated for 1 h at room temperature with a combination of secondary antibodies in buffer (4% normal donkey serum, 4% fish skin gelatin in PBS). Secondary antibodies were: donkey anti-goat AlexaFluor 488 (Molecular Probes) 1:300 and donkey anti-rabbit AlexaFluor 568 (Molecular Probes) 1:600.
Sections were washed a further three times in PBS and then mounted in Vectashield (Vector Labs) before visualisation through a x40 objective with oil immersion using a Zeiss LS510 Axiovert confocal microscope.
Standard controls involving pre-absorbtion of the TRPM8 or 5-HT 1B R antibody with their peptide antigen (and primary antibody omission controls) were carried out and in each case abrogated staining.
Cell culture
DRGs from adult rats (normally 10-14 per animal) were dissected into Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum (FBS) and penicillin/streptomycin (Invitrogen). After centrifuging for 3 min at 500 g, medium was removed and collagenase (5 mg/ml) and dispase (1 mg/ml; Roche)
were added before incubation at 37ºC for 2 h. Following centrifugation at 500 g for 5 min, the supernatant was discarded and the precipitate was digested in 0.25% trypsin (Invitrogen) at 37ºC for 8 min. Then 0.25% trypsin inhibitor (Invitrogen) was added and the preparation was centrifuged at 500 g for 5 min. The supernatant was removed and the pellet was washed with DMEM/10% FBS and re-centrifuged at 1,000 g for 5 min. After removing the supernatant, the pellet was re-suspended in DMEM/10% FBS and triturated to dissociate to a single cell suspension. This suspension was filtered through a 15% bovine serum albumin (BSA) solution (Sigma) by centrifugation at 500 g for 10 min and re-suspended in DMEM/10% FBS. The cell suspension was then purified through a Percoll solution comprising; 1 ml of 10x Hanks' Balanced Salt Solution (HBSS, Invitrogen), 1 ml 0.35% NaHCO 3 , 5 ml de-ionised H 2 O, 30 µl 1M HCl and 3 ml of 1.13 g/ml Percoll solution (Sigma), by centrifugation at 9,000 g for 10 min at 4 o C. The lower Percoll layer was re-suspended in DMEM/10%FBS and centrifuged for 10 min at 9,000 g. The cell pellet was resuspended in Neurobasal medium with B-27 supplement (Invitrogen), penicillin/streptomycin (1:100), L-glutamine (1 mM, Invitrogen), NGF (50 ng/ml; Roche), GDNF (2 ng/ml; Roche) and cytosine β-D-arabinoside hydrochloride (10 µM; Sigma).
Following plating onto coverslips coated with poly-D-lysine (Sigma), cells were incubated at 37ºC in an atmosphere containing 5% CO 2 and used the following day for calcium imaging.
Clonal lines of HEK 293 cells stably expressing human TRPM8, TRPV1 or TRPA1 were generated and previously characterised. Wild-type HEK 293 cells were used in some control experiments. Cells were plated out at a density of 1.5 x 10 5 cells/well in 24-well plates previously coated with fibronectin (0.01 mg/ml; Sigma).
Final volume was made up to 1 ml using complete DMEM without Phenol Red, containing 10% FBS and cells were then incubated at 37°C for 24 h to reach 60-80% confluency before transfection using FuGENE6 (Roche) with FLAG-tagged 5-HT 1B R and HA-tagged wild-type or catalytically inactive PLD constructs or empty plasmid as appropriate (Barclay et al., 2011 (Rohacs et al., 2005) . Cells were then grown at 37°C under 5% CO 2 for 48 h before assay.
Synaptoneurosome preparation
New protocols were developed to enable measurement of dynamic Ca 2+ fluorescence responses in synaptoneurosomes (resealed pre-synaptic and closely apposed post-synaptic elements) freshly prepared from CNS tissue (Hollingsworth et al., 1985; Villasana et al., 2006 ) using a range of technical modifications to help preserve metabolic and ionic integrity. Appropriate ipsilateral hemisected spinal cord segments and bilateral frontal or somatosensory cortex regions were removed from animals under 4% isoflurane/O 2 anaesthesia and rapidly homogenised in ice-cold, highly oxygenated medium using a hand-held teflon-glass homogeniser. This consisted of: divalent ion-free Krebs-Henseleit buffer additionally containing HEPES (10 mM, pH 7.4), sodium pyruvate (0.5 mM), glutathione (5 µM), creatine phosphate (2 mM), magnesium chloride (5 mM) and sodium kynurenate (0.3 mM). The homogenate was rapidly syringe-filtered through 100 µm and 30 µm nylon mesh filters and then though a 5 µm pore mixed cellulose fibre matrix filter (Millipore) before centrifugation at 1,500 g for 8 min at 4ºC. The pellet was resuspended in ice-cold highly oxygenated medium as above but lacking magnesium and kynurenate and containing 2 mM calcium chloride. Electron microscopic analysis of this subcellular fraction revealed the abundant presence of small dual-compartment re-sealed profiles consistent with the previously described characteristics of synaptoneurosomes (Hollingsworth et al., 1985) .
Measurement of cellular and synaptoneurosome calcium fluorescence responses
Ratiometric calcium imaging of single DRG neurons was carried out using Fura-2/AM dye (Invitrogen). Cells were loaded with 3.5 µM Fura-2/AM in DMEM supplemented with 0.1% Pluronic acid (Invitrogen) for 20 min. Following washing, coverslips were placed in a recording chamber containing 2.5 ml of DMEM. An Olympus BX50WI microscope was used for imaging (20x magnification objective lens). Pairs of images were collected every 5 s from alternating 70 ms exposures at 340 nm and 380 nm using a Photonics LPS150 monochromator and captured using a Hamamatsu ORCA-ER CCD camera. Data were analyzed using Simple-PCI software (Hamamatsu Corporation, Sewickley, PA, USA). Coverslips were superfused with DMEM buffer at 0.5 ml/min, using a gravity driven perfusion system for exchange of solutions. Temperature was maintained at 28.5°C. Following selection of a suitable field of view, recording was initiated. Only icilin-responsive cells were selected for evaluation of further treatments with other agents, alone or in combination with icilin. The effects of drugs were evaluated by paired comparisons. After a baseline period of 10 min the first icilin treatment was applied for 6 min, followed by a wash out period of at least 10-min and the second drug treatment with icilin / CP 94253 alone or icilin plus CP 94253. Following subtraction of background fluorescence, the ratio of fluorescence at 340 nm and 380 nm was calculated. Area under the curve was determined for the responses to each of the paired treatments using GraphPad Prism 4.
For calcium fluorometry in transfected TRPM8-expressing HEK 293 cells, medium was removed from each well to leave 300 µl prior to the addition of 100 µl of medium containing the visible wavelength no-wash Ca For experiments with freshly isolated synaptoneurosomes, aliquots were dispensed into 24-well plates and Calcium 4 dye was added (at 2x the concentration suggested in the manufacturer's protocol). Plates were then incubated for 45 min at 37 o C under 95% O 2 / 5% CO 2 before incubation at 28 o C for 5 min, drug additions and then fluorometric assessment as described above. Spinal cord synaptoneurosomes were stimulated with combined activators of nociceptive afferents, ACB (AITC/capsaicin/bradykinin) and synaptoneurosomes from somatosensory or frontal cortex were stimulated with the broad spectrum glutamate receptor agonist, DLH (d,lhomocysteic acid). The target specificity of these stimuli was confirmed by experiments demonstrating the abrogation of responses to ACB in the presence of the TRPV1 inhibitor AMG 9810, 3 µM, the TRPA1
inhibitor HC-030031, 10 µM and the B 2 receptor antagonist HOE-140, 2 µM, and of responses to DLH in the presence of the NMDA receptor antagonist (+) MK-801, 2 µM and the mGluR5 antagonist MPEP, 2 µM.
Immunoprecipitation and Western blot
Cells were serum-deprived for 4 h in 10 ml of DMEM per 175 cm 2 flask. Cells were then homogenised in 2 ml of ice-cold IP buffer (20% glycerol, 1% CHAPS, 1% sodium deoxycholate, 1 mM sodium orthovanadate in HEPES 20 mM/NaCl 150 mM buffer, pH 7.4), with 1:100 protease inhibitor cocktail 3 (Calbiochem). Flasks were kept on ice for 30-45 min and then cells were scraped and removed. For experiments involving spinal cord tissue, segments L4-L6 were collected from animals under anaesthesia with 4% isoflurane/oxygen. In order to minimise degradation, tissue was collected onto ice-cold foil, weighed, and promptly homogenised in 20 volumes of IP buffer. For immunoprecipitation, extracts were centrifuged at 10,000 g for 10 min at 4ºC to pellet remaining insoluble materials. The supernatants were then decanted and pre-cleared with Protein GSepharose CL-4B (20 µl 1:1 suspension in IP buffer/ml supernatant; Sigma) while rotating at 4ºC for 45 min, in order to remove any proteins that non-specifically bind to the beads. Following a pulse-spin the supernatant was removed and Protein G-Sepharose beads (40 µl suspension/ml) added together with the relevant antibody.
For immunoprecipitation of the FLAG-tagged 5-HT 1B R, a mouse monoclonal anti-FLAG antibody (M2) was used (4 µg/ml; Sigma). For TRPM8 immunoprecipitation, a rabbit polyclonal anti-TRPM8 antibody was used (7 µg/ml; Alomone). For immunoprecipitation of HA-tagged PLD1, a mouse monoclonal anti-HA antibody, 12CA5 was used (5 µg/ml; Roche). As controls, non-immune IgG of the same species as the antibody were used for mock pull-downs. Primary antibodies and non-immune IgGs were incubated with samples overnight at 4ºC. Samples were then centrifuged and the supernatants discarded. The beads were then washed three times with ice-cold IP buffer after which all liquid was removed and a volume of Laemmli buffer (85% Tris buffer (tris-hydroxymethylaminoethane, 50 mM, pH 7.4, Sigma; 5% mercaptoethanol, Sigma; 2% sodium dodecyl sulphate, SDS, Sigma) equal to that of bead suspension was added to each tube. The samples were thoroughly 
Cellular phospholipase D (PLD) activity assays
Medium was removed from TRPM8-expressing or wild type HEK 293 cells previously transfected with the 5-HT 1B R or the 5-HT 1A R in 12-well plates and replaced with DMEM (0.5 ml) containing [ 3 H]palmitic acid (1.5 µCi/well; Perkin Elmer Biosciences). After 18 h incubation at 37 o C in a 5% CO 2 atmosphere, the medium was replaced with Minimum Essential Medium (MEM, 0.5 ml) containing HEPES (25 mM, pH 7.5) and fatty acid-free bovine serum albumin (0.5%). To allow assessment of the transphosphatidylation activity of PLD, butan-1-ol (30 mM) was added to each well, immediately followed by the addition of 5-HT 1B R agonist. In experiments with selective PLD1 or PLD2 inhibitors, these agents were added 5 min before the butan-1-ol.
Responses were terminated after 20 min by the removal of medium and addition of ice-cold methanol (0.5 ml/well). Phospholipids were extracted and [ 3 H]phosphatidylbutanol ([ 3 H]PtdBut) was separated on thin layer chromatography plates (LK5D; Whatman) and quantified by liquid scintillation counting as described previously (Barclay et al., 2011) .
Cellular forskolin (FSK)-induced cyclic AMP production assays
Medium was removed from TRPM8-expressing HEK 293 cells previously transfected with the 5-HT 1B R in 24-well plates and replaced with DMEM (0.5 ml). After 4 h, the medium was replaced with MEM (0.5 ml)
containing HEPES (25 mM, pH 7.5) and 0.5 mM isobutylmethyl xanthine (IBMX, Sigma), a broad-spectrum phosphodiesterase inhibitor. 5-HT 1B R agonist was added immediately before the adenylyl cyclase activator forskolin (5 µM, Sigma) and incubations continued for 10 min at 37 o C before aspiration of medium and cell lysis in ice-cold 0.1 M HCl. The cyclic AMP (cAMP) content in aliquots of the lysis supernatant was then measured in duplicate by enzyme-linked immunoassay (EIA) kit (Cayman Chemical Company, 581001). Data were calculated as percentage of FSK-induced increment in cAMP production remaining in the presence of 5-HT 1B R agonists.
Cellular PIP 2 production assays
The medium of TRPM8-expressing HEK 293 cells in 12-well plates that had been transfected with the 5-HT 1B R or empty vector was replaced with MEM containing HEPES (25 mM, pH 7.5). 5-HT 1B R agonist was added (with/without selective PLD1 inhibitor) and assays continued for a range of times before they were terminated by aspiration and the addition of 1 ml ice-cold trichloroacetic acid. Cells from 2 wells per assay determination were scraped and processed before extraction of acidic phospholipids and analysis by specific PIP 2 mass ELISA (Gray et al., 2003) The bar chart illustrates that integrated area under the curve values for a second response to icilin plus CP 94253 were significantly greater than the first response to icilin alone. Dual label immunofluorescence histochemistry showed that the great majority (75-80%) of the small TRPM8-positive cell bodies in DRG additionally stained for the 5-HT 1B R (Fig. 1B) while a variety of other DRG cells (of a range of sizes) were positive for 5-HT 1B R and not TRPM8.
Results
Enhancement of TRPM8 responses to icilin by 5-HT 1B R activation in DRG cells and in HEK 293 cells coexpressing TRPM8/5-HT 1B R
In order to explore the nature of the facilitatory effect of 5-HT 1B R activation, we set up a cell model in which HEK 293 cells (considered to lack any endogenous 5-HT receptors (Lesage et al., 1998; Monsma et al., 1993) that had been stably transfected with TRPM8 were transiently transfected with the 5-HT 1B R. Using a fluorometric plate reader assay with a visible wavelength no-wash Ca 2+ fluorophore, Calcium 4, more convenient for higher throughput analysis in plastic multi-well plates, we confirmed that Ca 2+ elevation responses to submaximal concentrations of icilin were significantly facilitated by CP 94253 ( Fig. 2A) (Table 1) .
Physical association of the 5-HT 1B R and the TRPM8 channel
In a small number of cases, G protein-coupled receptors (GPCRs) have been reported to associate physically with ion channels to form channel-regulating complexes (Davare et al., 2001; Lavine et al., 2002; Li et al., 2010; Shukla et al., 2010) . There is also evidence, from the TRPV1 channel in particular, that GPCR-controlled signalling enzymes and their adapter proteins may bind to the channel (Chaudhury et al., 2011; Zhang et al., 2008) or that GPCR-generated second messengers may directly modulate it (Kim et al., 2009 ). We explored here whether a direct interaction may occur between the 5-HT 1B R and the TRPM8 channel. When FLAGtagged 5-HT 1B Rs were transiently expressed in the stable TRPM8-expressing HEK 293 cell line, we identified capture of FLAG-5-HT 1B R in TRPM8-directed pulldowns but not in non-immune IgG controls (Fig. 3A) . This was corroborated by the converse experiment in which TRPM8-immunoreactivity was specifically captured in FLAG-5-HT 1B R pulldowns but not controls (Fig. 3B) . Prior exposure to receptor agonist did not appear to be necessary. Despite the fact that native tissues express these antigens only in low abundance, we carried out corresponding in vivo experiments using spinal cord lysates. Although more non-specific and reagentassociated bands were evident, these confirmed that 5-HT 1B R-directed pulldowns compared to non-immune IgG controls specifically captured native TRPM8 immunoreactivity (Fig. 3C) . Converse experiments are illustrated in Fig. 6E . These findings support the idea that stable complexes can be formed between 5-HT 1B Rs and TRPM8 ion channels, both in a cell line model and in vivo.
Signalling events underlying the functional influence of the 5-HT 1B R on the TRPM8 channel
The 5-HT 1B R is primarily coupled to G proteins of the G i /G o family, leading to inhibition of adenylyl cyclase and opening of K + channels, but can activate additional intracellular signalling pathways, including PLD (Hinton et al., 1999) . PLD has been implicated in the regulation of TRPC3 channels by GPCRs, although the molecular basis is not clear (Glitsch, 2010; Kwan et al., 2009) . Second messenger-regulated kinases generally seem to exert inhibitory effects on TRPM8 (De Petrocellis et al., 2007; Premkumar et al., 2005; Sarria and Gu, 2010) . It has been reported that the alpha subunit of G q (Gα q ) can interact with TRPM8 to directly cause channel inhibition (Zhang et al., 2012) , although a contrasting report describes Gα q -dependent activation of PLC to hydrolyse phosphatidylinositol 4,5-bisphosphate (PIP 2 ) and lead to Ca 2+ mobilisation (Klasen et al., 2012) . There is a strong consensus of evidence that maintenance of optimal TRPM8 channel function is dependent on adequate levels of PIP 2 being present (Daniels et al., 2009; Liu and Qin, 2005; Rohacs et al., 2005) . Notably, PLD activity increases the rate of PIP 2 synthesis by upregulation of the PIP 2 -synthetic enzyme, phosphatidylinositol 4-phosphate (PIP) 5-kinase (Cockcroft, 2009 ). We therefore asked whether elevation of PIP 2 levels by 5-HT 1B R-mediated PLD activity might be a plausible mechanism for the potentiation of TRPM8 function. Using stable TRPM8-expressing cells, transiently transfected with the 5-HT 1B R, we took both pharmacological and molecular approaches to assess whether PLD and potentially its role in generating PIP 2 might be involved in the enhancement by CP 94253 of Ca 2+ responses to a low concentration of icilin (Fig. 4) .
The effect of CP 94253 was significantly attenuated in the presence of selective PLD inhibitors; VU0155069, halopemide, raloxifene and calphostin C , at concentrations that had no effect alone (Fig.   4A ). As calphostin C can also inhibit PKC following photoactivation, we confirmed that the PKC inhibitor bisindolylmaleimide 1 did not mimic the effect of the PLD inhibitors. To address whether modulation of PIP 2 levels might be important, we firstly tested wortmannin (an inhibitor, not only of phosphatidylinositol (PI) 3-kinase, but also less potently, of PI 4-kinase, which is essential for PIP 2 synthesis) and found that this too reversed the effect of CP 94253. In addition, a synthetic activator of phospholipase C (PLC), (which breaks down PIP 2 ), m-3M3FBS, abrogated the effect of CP 94253, whereas a PLC-β inhibitor, U-73122, caused a modest but significant facilitation. To further specify the role of PLD in 5-HT 1B R-mediated facilitation of TRPM8, we tested the effects of new highly selective inhibitors of PLD1 and PLD2 isoforms VU0359595 and VU0285655-1, respectively on CP 94253-induced enhancement of Ca 2+ responses to icilin (Fig. 4B ). affinity of VU0359595 and its marked 1700-fold selectivity for PLD1 over PLD2 (Lewis et al., 2009) , together with similar but more modest 163-fold selectivity of VU0155069 ), compared to the 21-fold selectivity of VU0285655-1 for PLD2 over PLD1 (Lavieri et al., 2009 ), these observations clearly implicate PLD1 rather than PLD2. In further experiments, we co-transfected dominant negative constructs of PLD1 or PLD2 and showed that only the dysfunctional PLD1 construct significantly attenuated the CP 94253 facilitation of icilin responses (Fig. 4C) maximal response (± SEM) of 45.9 ± 6.1% reduction from control (n=4). These experiments indicate that PLD1 but not PLD2 is a mediator of 5-HT 1B R facilitation of TRPM8 channel function and point to the idea that its influence on PIP 2 levels may underly this effect.
To address directly candidate events occurring downstream of PLD1 activation by the 5-HT 1B R we evaluated the role of PIP 5-kinase, PIP 2 production and PIP 2 action on the TRPM8 channel. 5-HT 1B R plus TRPM8-expressing HEK 293 cells were co-transfected with wild-type PIP 5-kinase 1β, a negative mutant construct defective in activation by the PLD product phosphatidic acid [YKRR209VAAE, R215D]PIP 5-kinase 1β (Stace et al., 2008) or empty vector (Fig. 5A ). The facilitation of Ca 2+ fluorescence responses caused by CP 94253 in vector-transfected cells was maintained in the presence of wild-type PIP 5-kinase but strongly and significantly attenuated in the presence of the mutant construct. This indicates that PIP 5-kinase recognition of and activation by phosphatidic acid is a key step in the mechanism of 5-HT 1B R facilitation of the TRPM8 channel. Measurement of the time course of PIP 2 concentration by PIP 2 mass ELISA (Gray et al., 2003) showed a significant but transient peak in the first 5-10 min of stimulation with CP 94253 in TRPM8-expressing HEK 293 cells that had been transfected with 5-HT 1B R but not those transfected with vector alone (Fig. 5B) . The peak in PIP 2 production was largely and significantly attenuated in the presence of a low concentration of the PLD1-selective inhibitor VU0359595 (100 nM), indicating that 5-HT 1B R-induced PIP 2 production is dependent on PLD1 activity. 
Phospholipase D1 is physically associated with the 5-HT 1B R and TRPM8 channel
As several GPCRs, including 5-HTR subtypes, interact directly with PLD (Barclay et al., 2011) we explored whether the 5-HT 1B R might also interact with PLD1 in particular, especially when associated with TRPM8.
PLD contributes to GPCR regulation of TRPC3 channels (Glitsch, 2010; Kwan et al., 2009 ) but there is no prior evidence of direct PLD:channel interaction. Using TRPM8-expressing HEK 293 cells co-transfected with FLAG-5-HT 1B R and HA-PLD1, we specifically captured HA-PLD1 in TRPM8-directed pulldowns but not non-immune IgG controls (Fig. 6A ). This interaction was corroborated by converse experiments in which TRPM8 was specifically captured in HA-directed pulldowns but not controls (Fig. 6B ). In addition FLAGdirected pulldowns captured HA-PLD1 (Fig. 6C ) and HA-directed pulldowns captured 5-HT 1B R (Fig. 6D) . In spinal cord lysates, despite the presence of various non-specific and reagent-associated bands, we identified that TRPM8-directed pulldowns compared to non-immune IgG controls specifically captured native PLD1 and 5-HT 1B R (Fig. 6E) . Native 5-HT 1B R pulldowns are illustrated in Fig. 3C but we did not attempt to carry out native PLD1-directed pulldowns because of the lack of adequate reagents and the low level yet ubiquitous expression of PLD isoforms. These findings establish directly the existence of a regulatory complex between a GPCR, a TRP channel and PLD both in cell models and in vivo.
5-HT 1B R activation in vivo potentiates TRPM8-mediated inhibition of pain state-associated neural hyperresponsiveness and reflex pain behaviours
To evaluate whether 5-HT 1B Rs could facilitate the anti-nociceptive influence of TRPM8 that has been described in vivo (Dhaka et al., 2007; Knowlton et al., 2013; Liu et al., 2013; Proudfoot et al., 2006; Su et Figure 7B , showing ACB-or DLH-induced increments in Ca 2+ fluorescence above basal, normalised to ionomycin-induced increments, illustrates that CFA, 24 h previously, significantly amplified stimulus-evoked responses to ACB in spinal cord (on ipsilateral, and to a lesser extent contralateral, sides) and to DLH in both cortical regions. This accords with the widespread activating changes elicited by CFA at not only spinal but also supraspinal levels of the CNS (Samad et al., 2001 ). Each of these enhancements was reversed by topical administration of icilin (200 µM in aqueous 1% dimethylformamide) to the hindpaws for 15 min under general anaesthesia prior to tissue removal. As described previously (Proudfoot et al., 2006) , the concentration of icilin reaching TRPM8 on fine afferent terminals largely around the epidermal/dermal border is expected to be many fold less than that externally applied. Mean ACB-evoked Ca 2+ fluorescence responses in ipsilateral spinal cord synaptoneurosomes, averaged over 6 readings at 30-s intervals starting 1 min into the recording period and normalised to maximal ionomycin-evoked responses, were 15.3 ± 2.7% (naïve); 34.4 ± 7.0% (CFA); 12.2 ± 3.1% (CFA with topical icilin). Analysis by One-Way ANOVA with Tukey's post hoc test indicated that the CFA-induced enhancement of responses and the reversal of this following icilin were both statistically significant (p<0.05, n=4-5). Vehicle had no discernible effect on responses from CFA-injected animals (37.0 ± 8.1%, n=4). Similarly in synaptoneurosomes from somatosensory and frontal cortex, responses to DLH were 12.5 ± 1.1% and 13.4 ± 0.6% (naïve); 19.6 ± 3.0% and 22.4 ± 2.4% (CFA); 6.4 ± 4.2% and 10.0 ± 3.5% (CFA with topical icilin) respectively, with icilin reversal of the enhancement being statistically significant in each case (p<0.05 and p<0.01, n=3-5).
To investigate whether 5-HT 1B R activation could potentiate this TRPM8-mediated influence we tested lower concentrations of icilin in combination with the 5-HT 1B/1D R agonist sumatriptan in a topical vehicle (propan 1,2-diol containing 1.5% caprolactam) that has been previously shown to enhance skin penetration of compounds including sumatriptan (Femenia-Font et al., 2006; Williams, 2003) and is compatible with icilin uptake via this route (Proudfoot et al., 2006) . Figure 7C shows that the enhanced mean Ca 2+ fluorescence responses of ipsilateral spinal cord synaptoneurosomes to ACB in CFA-injected animals were significantly reduced by topical administration in vivo of icilin (50 µM) plus sumatriptan (100 µM) prior to tissue removal, whereas either drug alone or vehicle had no significant effect. The combined effect of icilin plus sumatriptan was significantly reversed by topical in vivo co-administration of the 5-HT 1B R antagonist SB 224289 (120 µM).
Furthermore, while a relatively low topical concentration of menthol (1 mM) did not significantly reduce ACB responses, in the additional presence of sumatriptan (100 µM), statistically significant inhibition was observed, as seen with icilin. Similarly in somatosensory and frontal cortex, the enhanced responses to DLH seen following CFA injection were significantly reduced by topically applied icilin (110 µM) plus sumatriptan (165 µM), neither of which had a significant effect alone. Thus the widespread CNS hyper-responsiveness caused by inflammation can be attenuated by peripheral topical administration of TRPM8 agonist in vivo and this effect is amplified by co-activation of 5-HT 1B Rs in vivo.
We further asked whether co-activation of the 5-HT 1B R might actually make a contribution to TRPM8 achieving its full analgesic effect in chronic pain. CFA-injected animals were treated in vivo with 200 µM icilin applied topically to the hindpaws before measuring the Ca 2+ fluorescence responses of spinal cord synaptoneurosomes to ACB. This slightly higher concentration of icilin alone caused significant reversal of hyper-responsiveness, which was significantly attenuated by the selective 5-HT 1B R antagonists SB 224289, 120 µM or GR 55562, 200 µM, included in the topically applied solution, and almost completely abrogated by inclusion of the selective TRPM8 inhibitor AMTB, 200 µM but not affected by the 5-HT 1D R-selective antagonist BRL 15572, 150 µM (Fig. 8) . None of the antagonists topically applied alone had any discernible effect on spinal cord synaptoneurosome Ca 2+ responses to ACB in CFA-treated animals. Icilin, SB 224289 and AMTB were also tested in naive animals, where they displayed no discernible effect. Furthermore the 5-HT 1B R antagonists had no direct effect that could be detected on icilin responses in TRPM8-expressing HEK 293 cells whether or not these were transfected with the 5-HT 1B R. This suggests that TRPM8 requires the co-activation of the 5-HT 1B R in order to fully exert its reversal of chronic pain-associated hyper-responsiveness in the CNS.
In addition, we explored whether reflex pain behaviours in chronic pain models were affected in a similar way. Figure 9A shows that in CFA-injected animals, the ipsilateral reduction in paw withdrawal latency to noxious heat (Hargreaves' test) (Proudfoot et al., 2006) was significantly reversed towards contralateral and naive values by the in vivo topical administration of icilin (50 µM) plus sumatriptan (100 µM), whereas the effects of either alone were not significant. Figure 9B shows that a higher concentration of topically applied icilin (200 µM) significantly reversed CFA-induced hypersensitivity on its own and that this effect of icilin was strongly attenuated in the additional presence of SB 224289 (120 µM), which had no discernible effect alone.
The synergy between low topical concentrations of icilin and sumatriptan in reversing CFA-induced hypersensitivity was replicated with an alternative TRPM8 activator, menthol (1 mM), which caused significant reversal only in the presence of sumatriptan (Fig. 9C ). Figure 9D further shows that in the CCI model of neuropathic pain the sensitised ipsilateral Hargreaves' responses were only marginally reduced by a low intrathecal dose of icilin (2.5 nmole) but this became statistically significant when icilin was co-administered with CP 94253 (2.5 nmole), which had no significant effect alone. The newly identified TRPM8:5-HT 1B R:PLD1 signalling complex thus appears to play an important physiological role in vivo in enabling 5-HT 1B R amplification of the analgesia exerted by TRPM8 on sensitised pain behaviours and further seems to be necessary for TRPM8 to exert its full impact on chronic pain.
In control experiments we investigated whether alternative acute behavioural responses to icilin administration were affected by 5-HT 1B R agents. Firstly we investigated "wet dog shakes" induced by intraperitoneal injection of icilin (Wei, 1981; Werkheiser et al., 2009) . Icilin (0.5 mg/kg elicited 65.4 ± 8.3
shaking/shuddering events from 5-25 min following injection (mean ± SEM, n=5), a response that was not discernibly altered in the presence of either sumatriptan (0.3 mg/kg; 60.6 ± 9.0 events, n=4) or SB 224289 (3 mg/kg; 56.7 ± 8.2 events, n=4). Injection of vehicle elicited no events. The lack of any significant effect (OneWay ANOVA with Dunnett's post hoc test) indicates that pharmacological interventions at the 5-HT 1B R do not impact on this behavioural response to intraperitoneal icilin, at least under the conditions tested. Secondly as nocifensive behaviours can be elicited by direct intraplantar administration of high concentrations of icilin (Knowlton et al., 2010) and response thresholds to thermal and mechanical stimuli are reduced at very high icilin or menthol concentrations (Dhaka et al., 2007; Gentry et al., 2010; Proudfoot et al., 2006) , we 
Discussion
To address the hypothesis that functional activation of the TRPM8 ion channel might be facilitated by a GPCR such as the 5-HT 1B R, we carried out a range of in vitro and in vivo experiments. Using single cell Ca 2+ fluorometry on isolated DRG cells we identified the subpopulation that responded to the TRPM8 agonist icilin and then showed that they displayed a much greater response to a subsequent challenge with icilin plus a selective 5-HT 1B R agonist (CP 94253), which had no effect alone. Dual label immunofluorescence revealed that around 80% of the small TRPM8-positive cells in DRG also express the 5-HT 1B R. We therefore set up a cell line model of HEK 293 cells stably expressing TRPM8 that were transiently transfected with the 5-HT 1B R.
Their Ca 2+ fluorescence responses to a low concentration of icilin or menthol were strongly increased in the presence of CP 94253 or the selective 5-HT 1B/1D R agonist sumatriptan and the potentiation was abrogated by the selective 5-HT 1B R antagonist SB 224289. In contrast the 5-HT 1A R was unable to enhance TRPM8 responses and the 5-HT 1B R was unable to enhance TRPV1 or TRPA1 responses, emphasising the specificity of the interaction observed here. There are several examples of GPCRs forming physical complexes with Ca 2+ and K + channels (Davare et al., 2001; Lavine et al., 2002; Li et al., 2010) but only a single report of direct association with a TRP family channel, in which the angiotensin AT 1A R forms a complex with TRPV4 and β-arrestin 1 in vascular smooth muscle cells (Shukla et al., 2010) . We found compelling evidence here from coimmunoprecipitation in the cell model and in vivo that the 5-HT 1B R was directly associated with TRPM8.
We next considered whether signalling by the 5-HT 1B R might mediate its facilitatory influence on TRPM8. In the cell model, CP 94253-enhanced icilin-evoked Ca 2+ fluorescence responses were challenged with key pharmacological and molecular reagents. Several signalling pathways have been reported to modulate TRPM8.
Gα q is reported to interact directly with TRPM8 and inhibit the channel through an unknown mechanism that may not involve activation of PLC-β and PIP 2 hydrolysis (Zhang et al., 2012) . However a contrasting report indicates that interaction with TRPM8 causes activation of Gα q and downstream PLC signalling (Klasen et al., 2012) . PKC inhibits channel amplitude or activation threshold in response to menthol or cold and promotes desensitisation (Premkumar et al., 2005; Sarria and Gu, 2010) . PKA does not affect responses to relatively high concentrations of menthol (Bavencoffe et al., 2010; Sarria and Gu, 2010) , but can inhibit responses to submaximal concentrations of icilin or menthol (De Petrocellis et al., 2007) . Lysophospholipids generated by phospholipase A 2 can facilitate TRPM8 activation, whereas polyunsaturated fatty acids that are produced concomitantly exert inhibitory effects (Andersson et al., 2007; Bavencoffe et al., 2011) . Raised cytosolic Ca 2+ concentrations may contribute to channel desensitisation by PKC activation or depletion of PIP 2 (Rohacs et al., 2005) , which is an essential co-factor for TRPM8 channel function. Reasoning that processes leading to increased PIP 2 levels such as PLD activation (Cockcroft, 2009 ) could potentially be involved in the facilitatory influence of the 5-HT 1B R on TRPM8, we showed that selective inhibitors of PLD blocked the effect of CP 94253. The effects of wortmannin, an inhibitor of PI 4-kinase, needed for PIP 2 production and m-3M3FBS / U-73122, an activator and inhibitor respectively of PLC, which breaks down PIP 2 , were each consistent with this hypothesis. PLD1 rather than PLD2 was implicated by reversal of the 5-HT 1B R effect in the presence of selective pharmacological inhibitors for PLD1 but not PLD2 and by negative mutant PLD constructs. The 5-HT 1B R agonist CP 94253 caused robust activation of cellular PLD1 through a similar concentration range to its classical G i/o -mediated response of inhibiting forskolin-stimulated cAMP production. Further coimmunoprecipitation experiments revealed that the key signalling enzyme PLD1 was additionally docked in the 5-HT 1B R:TRPM8 complex, both in the cell model and in vivo. In addition, we provided direct evidence for the subsequent involvement of PIP 5-kinase in the PLD1-dependent facilitatory effect of 5-HT 1B R on the channel as the effect was abrogated by transfection of a phosphatidic acid-unresponsive PIP 5-kinase mutant.
Furthermore we showed that 5-HT 1B R activation caused a transient rise in cellular PIP 2 concentration that was
prevented by PLD1 inhibitor and demonstrated that a TRPM8 mutant construct with greatly reduced PIP 2 responsiveness failed to show the 5-HT 1B R-mediated facilitation seen with the wild-type channel. Taken together, these findings point strongly to the existence of a 5-HT 1B R:TRPM8:PLD1 complex that can achieve upregulation of TRPM8 function by PLD signalling leading to increased levels of PIP 2 ; a positive allosteric modulator of channel function.
To examine the physiological significance of 5-HT 1B R:TRPM8 interactions we carried out experiments in both inflammatory (CFA) and neuropathic (CCI) pain models, assessing the impact on pain state-associated hyper-responsiveness to excitatory stimuli in ex vivo synaptoneurosomes or on sensitised pain behaviours in vivo. We administered 5-HT 1B R agonists and TRPM8 activators topically to the skin of the hindpaws or intrathecally to the spinal cord. A selective 5-HT 1B/1D R agonist sumatriptan amplified the effect of low concentrations of icilin or menthol in reversing CFA-induced hyper-responsiveness of synaptoneurosomes from spinal and supraspinal CNS regions, with 5-HT 1B R specificity confirmed through reversal by SB 224289. At slightly higher concentrations, icilin alone produced a similar outcome, which could be attenuated by SB 224289 or GR 55562, indicating a functional dependence of TRPM8 on the associated 5-HT 1B R in order to achieve its full influence of reversing hypersensitivity in chronic pain. Icilin, SB 224289 or the TRPM8 antagonist AMTB alone had no effect on responsiveness of spinal cord synaptoneurosomes from naive animals, suggesting that TRPM8 or tonic activation of the TRPM8/5-HT 1B R complex exert a substantive modulatory influence only in chronic pain states. These observations were paralleled by matching reversals of sensitised pain behaviours both in the CFA model following topical application of agents to the hindpaw skin and in the CCI model following intrathecal drug administration (accessing peripheral and central terminal regions of TRPM8 afferents respectively). Again, icilin or menthol in combination with 5-HT 1B R agonist, slightly higher levels of icilin alone or SB 224289 alone had no effect on contralateral behavioural responses. Thus the TRPM8:5-HT 1B R:PLD1 complex in sensory afferents appears to play an important role in the analgesic effect of TRPM8 activation in vivo, particularly in chronic sensitised pain states. Our data showing that the efficacy of slightly higher concentrations of icilin alone, in the CFA model of inflammatory pain, is attenuated by 5-HT 1B R antagonist suggest tonic activation of the 5-HT 1B R component of the complex in the chronic pain state. 5-HT that could achieve this activation is likely to be released into the peripheral inflammatory milieu from various sources including platelets (Khalil and Helme, 1990; Shu and Mendell, 1999) . It is possible that central spinal release of 5-HT in pain states could also affect the TRPM8:5-HT 1B R:PLD1 complex on central terminals of relevant afferents but our experiments did not address that question, as the topical application of drugs to the hindpaw is unlikely to achieve effective concentrations in spinal cord.
The 5-HT 1B R facilitation of TRPM8 function in non-nociceptive afferents that exert antihypersensitivity/analgesic actions appears to contrast with effects on other acute behavioural responses to icilin that are seen after its direct administration at much higher concentrations, yet are TRPM8-dependent and thought to be peripherally mediated (Colburn et al., 2007; Dhaka et al., 2007; Knowlton et al., 2010; Knowlton et al., 2013; Pogorzala et al., 2013) . In the "wet dog shakes" model of shaking/shuddering induced by intraperitoneal injection of icilin (Wei, 1981; Werkheiser et al., 2009 ), co-administration of 5-HT 1B R agonist or antagonist (at doses known to be efficacious in other contexts) had no apparent effect. In a model of nocifensive behaviour induced by intraplantar injection of icilin (Knowlton et al., 2010) , co-administration of 5-HT 1B R agonist attenuated rather than exacerbated the response. In these models the concentrations of icilin solution (1.6-3.2 mM) directly applied to the peritoneal space (where the drug may potentially access visceral afferents) or close to cutaneous afferent terminals within the skin are far higher than those (50-200 µM), which when applied topically to the outside of the skin showed useful anti-hypersensitivity/analgesic actions, either alone or in combination with 5-HT 1B R agonist. It is further likely that after topical application the concentrations of drugs actually reaching TRPM8 afferents at the epidermal/dermal border are greatly reduced by limited penetration of the stratum corneum and dilution due to diffusion. Likewise, the concentration of 5-HT 1B R agonist that attenuated nocifensive responses in the intraplantar model (2 mM) is considerably higher than the low topical concentrations (100-165 µM) that had no significant anti-hypersensitivity/analgesic effect alone but displayed remarkable synergy with low concentrations of TRPM8 activators. Taken together these findings indicate that while 5-HT 1B R agonists have the advantageous effect of amplifying the antihypersensitivity/analgesic effects of low levels of TRPM8 activator, presumably acting on non-nociceptive afferents, they either do not affect or attenuate the unfavourable, potentially nociceptor-associated effects ("wet dog shakes" or intraplantar nocifensive response, respectively) elicited by direct administration of very high icilin concentrations. This profile emphasises the therapeutic potential of co-administration of low levels of TRPM8 activators and 5-HT 1B R agonists in the treatment of chronic pain, especially via the topical route.
Analgesic actions of triptans alone have been reported but these generally appear to be limited to supraspinal levels; for example, following systemic administration, triptans attenuate nociceptive responses of single trigeminal but not spinal dorsal horn neurons (Cumberbatch et al., 1998) . Triptan attenuation of non-cranial inflammatory and capsaicin-induced hyperalgesia has been described however, with evidence for both central and peripheral sites of action (Loyd et al., 2012; Nikai et al., 2008) but this displays a predominantly 5-HT 1D -like profile, although 5-HT 1B R(s) may contribute (Godinez-Chaparro et al., 2013) . The actions of 5-HT 1B/1D agents here display a distinct 5-HT 1B R rather than 5-HT 1D R profile and are seen exclusively in co-operation with TRPM8. Triptans are important clinically in the treatment of migraine where their target 5-HT 1B/1D Rs, present on meningeal afferents are thought to play a key role in the mechanism of action (Levy et al., 2004) , although receptors at other peripheral and central locations may also be important. Interestingly, recent genome-wide association studies have implicated a single nucleotide polymorphism close to the TRPM8 gene as a genetic risk factor for migraine (Chasman et al., 2011; Esserlind et al., 2013) . In addition, a preliminary clinical trial has reported the TRPM8 agonist menthol to be efficacious in the treatment of migraine (Borhani Haghighi et al., 2010) . These reports raise the possibility that TRPM8:5-HT 1B R interactions, similar to those described here in somatosensory afferents, might also occur in cerebrovascular afferents and in support of this hypothesis we observed co-expression of 5-HT 1B R in around 80% of TRPM8-expressing cells in trigeminal ganglion.
In summary we show here, in cell models, in ex vivo synaptic preparations and in vivo, that TRPM8 and the 5-HT 1B R interact directly in a novel signalling complex that incorporates PLD1, which mediates the facilitatory influence of the 5-HT 1B R on TRPM8 by means of its product phosphatidic acid acting on PIP 5-kinase to increase production of PIP 2 , an allosteric facilitator of the TRPM8 channel. This amplification of TRPM8 action by the 5-HT 1B R is important in TRPM8 reversal of pain state-induced synaptic hyper-responsiveness at both spinal and supraspinal levels and in the analgesic actions that TRPM8 activators exert over chronic pain.
The observation that a 5-HT 1B R antagonist can attenuate anti-hypersensitivity/analgesic effects of slightly higher levels of TRPM8 activator alone suggests that there may be some tonic activation of the 5-HT 1B R component of this complex in chronic pain states. Overall, these findings suggest that combination therapy with TRPM8 activators and 5-HT 1B R agonists (including via a topical route) could have the potential to provide more efficacious analgesia in the treatment of chronic pain states.
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